helped obese patients with Type 2 diabetes lose 15% of their body weight, or about 34 pounds, on average, in a late-stage clinical trial, the drugmaker said in a news release Thursday.— which is sold under the brand name Mounjaro for Type 2 diabetes — can be used as an effective weight loss aid.found that tirzepatide helped patients without Type 2 diabetes lose 22.5% of their body weight on average, or about 52 pounds. Patients in that trial had obesity or were overweight.
The participants in the trial received a weekly injection of tirzepatide or a placebo for 72 weeks. Two doses of tirzepatide were studied: a 10-milligram dose and a 15 mg dose. Thursday’s results were announced in a news release and haven’t been made available for peer review yet., said Dr. Susan Spratt, an endocrinologist and senior medical director for the Population Health Management Office at Duke Health in North Carolina.
مصر أحدث الأخبار, مصر عناوين
Similar News:يمكنك أيضًا قراءة قصص إخبارية مشابهة لهذه التي قمنا بجمعها من مصادر إخبارية أخرى.
مصدر: MarketWatch - 🏆 3. / 97 اقرأ أكثر »
مصدر: ABC - 🏆 471. / 51 اقرأ أكثر »